Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1014-1016. doi: 10.1051/medsci/2019224. Epub 2020 Jan 6.

[Monoclonal antibodies in cardiovascular diseases and metabolic disorders today].

[Article in French; Abstract available in French from the publisher]

Author information

1
Service de cardiologie CHRU de Tours et EA4245, Loire Valley Cardiovascular collaboration et Labex MabImprove, Université de Tours, Tours, France.
2
Unité d'hypertension artérielle, facteurs de risque et insuffisance cardiaque, Inserm U. 1048, Clinique Pasteur, Toulouse, France.

Abstract

in English, French

The use of monoclonal antibodies in cardiovascular diseases and metabolic disorders is still in its infancy. Recent development of anti-PCSK9 monoclonal antibodies for the treatment of dyslipidemia and of patients in secondary prevention is a breakthrough in the field. Anti- PCSK9 antibodies significantly improved LDL cholesterol reduction in patients with familial hypercholesterolemia. These antibodies have also demonstrated a significant reduction of clinical events in patients with previously established atherosclerotic disease such as myocardial infarction, ischemia stroke or peripheral artery disease. Other targets are under investigation such as inflammatory cells and cytokines to reduce atherosclerosis or myocardial lesions following myocardial infarction.

PMID:
31903910
DOI:
10.1051/medsci/2019224

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center